BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia
- PMID: 20058037
- DOI: 10.1007/s00702-009-0358-y
BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia
Abstract
Alzheimer's disease (AD) is characterized by a significant reduction in AcetylCholinesterase and an increase in ButyrylCholinesterase (BuChE) activity. The existence of polymorphic regions on the BuChE gene has been previously described; the most frequently found polymorphism is the so-called K variant, which leads to a 30% decreased enzymatic activity. Different studies reported a positive association between K variant and AD, strongest among late-onset AD and Apolipoprotein E (APOE) e4 carriers. We analyzed APOE and BuChE polymorphisms in 167 AD and 59 fronto-temporal dementia (FTD) patients compared with 129 healthy controls (HC). We reported a significantly lower frequency of the BuChE K variant in AD compared with HC and FTD and a significant increased frequency of the K variant in FTD. These results are in agreement with the known increase of the BuChE activity in AD and support the evidence of different molecular pathways involved in the pathogenesis of AD and FTD.
Similar articles
-
Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.Neurosci Lett. 2017 Feb 22;641:101-106. doi: 10.1016/j.neulet.2017.01.036. Epub 2017 Jan 17. Neurosci Lett. 2017. PMID: 28108398
-
Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.J Alzheimers Dis. 2012;28(2):443-58. doi: 10.3233/JAD-2011-111088. J Alzheimers Dis. 2012. PMID: 22012848
-
Butyrycholinesterase K variant and Alzheimer's disease.J Neurol. 1999 May;246(5):369-70. doi: 10.1007/s004150050365. J Neurol. 1999. PMID: 10399868
-
Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could BCHE Genotyping Be Helpful in Alzheimer's Therapy?Biomolecules. 2019 Oct 9;9(10):592. doi: 10.3390/biom9100592. Biomolecules. 2019. PMID: 31601022 Free PMC article. Review.
-
Targeting acetylcholinesterase and butyrylcholinesterase in dementia.Int J Neuropsychopharmacol. 2006 Feb;9(1):101-24. doi: 10.1017/S1461145705005833. Epub 2005 Aug 5. Int J Neuropsychopharmacol. 2006. PMID: 16083515 Review.
Cited by
-
A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Prim Care Companion CNS Disord. 2013;15(2):PCC.12r01412. doi: 10.4088/PCC.12r01412. Epub 2013 Mar 7. Prim Care Companion CNS Disord. 2013. PMID: 23930233 Free PMC article.
-
Confirmed Synergy Between the ɛ4 Allele of Apolipoprotein E and the Variant K of Butyrylcholinesterase as a Risk Factor for Alzheimer's Disease: A Systematic Review and Meta-Analysis.J Alzheimers Dis Rep. 2023 Jun 19;7(1):613-625. doi: 10.3233/ADR-220084. eCollection 2023. J Alzheimers Dis Rep. 2023. PMID: 37483326 Free PMC article.
-
Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.J Alzheimers Dis. 2017;56(1):229-237. doi: 10.3233/JAD-160562. J Alzheimers Dis. 2017. PMID: 27911294 Free PMC article.
-
Butyrylcholinesterase K variant and Alzheimer's disease risk: a meta-analysis.Med Sci Monit. 2015 May 16;21:1408-13. doi: 10.12659/MSM.892982. Med Sci Monit. 2015. PMID: 25978873 Free PMC article.
-
Association between butyrylcholinesterase K variant and mild cognitive impairment in the Thai community-dwelling patients.Clin Interv Aging. 2017 May 26;12:897-901. doi: 10.2147/CIA.S137264. eCollection 2017. Clin Interv Aging. 2017. PMID: 28603409 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous